Welcome to our dedicated page for Nyxoah SA Ordinary Shares news (Ticker: NYXH), a resource for investors and traders seeking the latest updates and insights on Nyxoah SA Ordinary Shares stock.
Nyxoah SA Ordinary Shares (symbol: NYXH) is at the forefront of medical technology, focusing on innovative solutions to address Obstructive Sleep Apnea (OSA). The company is committed to enhancing the lives of individuals suffering from sleep-disordered breathing conditions through its state-of-the-art products and services.
Nyxoah's flagship product, the Genio system, is a CE-Mark validated, bilateral neurostimulation therapy designed to treat moderate to severe OSA. This user-centered system provides an effective and non-invasive treatment option for a condition that has been linked to increased mortality risks and various comorbidities, including cardiovascular diseases, depression, and stroke.
The Genio system stands out in the market due to its unique approach, focusing on bilateral stimulation to open the airway during sleep, thereby improving the quality of life for patients. The development and commercialization of this innovative platform underscore Nyxoah's commitment to addressing critical health issues with cutting-edge technology.
Recent achievements of Nyxoah include advancements in clinical trials, expansion into new markets, and strategic partnerships that underscore the company's growth potential and dedication to innovation. Financially, Nyxoah has shown resilience and strategic foresight, ensuring robust investment in research and development to maintain its competitive edge.
Nyxoah continually updates its stakeholders with the latest company news, ensuring transparency and fostering investor confidence. With its headquarters in Belgium, Nyxoah is well-positioned to expand its global presence and continue its mission of providing effective solutions for OSA and related conditions.
Stay informed with the latest updates and developments from Nyxoah to keep track of their performance, events, and strategic initiatives.
Nyxoah (Euronext Brussels/Nasdaq: NYXH), a medical technology company focused on developing innovative Obstructive Sleep Apnea (OSA) treatments through neuromodulation, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The company will deliver a presentation on Wednesday, December 4, 2024, at 2:00pm ET.
Interested parties can access a live audio webcast of the presentation through the investor relations section of Nyxoah's website at investors.nyxoah.com.
Nyxoah SA announces a special shareholders' meeting scheduled for December 19, 2024, at 3:00 p.m. CET at the company's headquarters. The meeting will address the approval of clauses in the EIB Agreements, including a loan facility and synthetic warrant agreement with the European Investment Bank. Key points include Change-of-Control Event provisions and voting procedures.
Shareholders can participate in person or via video conference, with voting available through mail or proxy before December 13, 2024. Registration date is set for December 5, 2024. The meeting requires no specific quorum, and decisions will be adopted by simple majority vote. Each share entitles one vote.
Nyxoah SA announced receiving a transparency notification from ResMed Inc. regarding a passive threshold crossing. According to the notification dated November 5, 2024, ResMed Inc. now holds 1,727,864 voting rights, representing 4.62% of the total voting rights (37,389,015) as of October 9, 2024. This represents a decrease below the 5% threshold. ResMed Inc. is not a controlled entity and holds these voting rights directly without any indirect holdings.
Nyxoah reported third quarter 2024 financial results with revenue of €1.3 million, representing 30% growth versus Q3 2023. The company's total cash position reached €71.0 million at quarter-end, with an additional €24.6 million raised through an ATM program. Operating loss increased to €15.0 million from €11.0 million in Q3 2023. Research and development expenses were €7.9 million, up from €6.6 million year-over-year. The company remains on track for FDA approval in Q1 2025 and is building its U.S. commercial team, with cash runway extended until mid-2026.
Nyxoah has appointed John Landry as its new Chief Financial Officer, effective November 4, 2024. This appointment, along with CEO Olivier Taelman's recent move to the United States, reinforces the company's focus on the U.S. market. Landry brings over 20 years of financial leadership experience in healthcare and medtech, previously serving as CFO at Vapotherm Inc. Current CFO Loïc Moreau will transition to the newly created role of President International, where he will lead Nyxoah's global expansion efforts.
Nyxoah SA announced receiving a transparency notification from Vestal Point Capital following changes in voting securities. According to the notification dated October 22, 2024, Vestal Point Capital now holds 3,000,688 voting rights, representing 8.03% of total voting rights (37,389,015) as of October 9, 2024. The threshold of 5% was crossed. Vestal Point Capital, LP is controlled by Vestal Point Capital, (general partner), which is controlled by Ryan Wilder (managing member). Vestal Point Capital, LP serves as the investment management company with discretionary voting rights.
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), a medical technology company focused on innovative solutions for Obstructive Sleep Apnea (OSA), has announced the release of its third quarter 2024 financial results on November 6, 2024, after market close. The company will host a conference call to discuss the results on the same day at 10:30pm CET / 4:30pm ET.
Investors can access the call via webcast through the Investor Relations page of Nyxoah's website or a provided link. Those planning to ask questions should register using a separate link, which will provide dial-in details and a unique conference call access code. Registration is recommended at least 10 minutes before the call starts. An archived webcast will be available for replay after the call concludes.
Nyxoah SA (NYXH) received three transparency notifications following changes in shareholdings:
- Jürgen Hambrecht and JH Capital GmbH now hold 1,344,000 voting rights (3.91%) after crossing the 3% threshold on September 5, 2024.
- BlackRock, Inc. and related entities initially reported holding 1,116,421 voting rights (3.25%) on October 8, 2024, crossing the 3% threshold.
- However, BlackRock's holdings subsequently fell to 2.99% (1,116,421 voting rights) on October 9, 2024, due to a passive downward crossing of the 3% threshold.
These notifications were made in accordance with Belgian transparency regulations for large shareholdings.
Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) has released an update on its total number of voting rights and shares as of October 9, 2024. This disclosure is in compliance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings. The key details are:
Share capital: EUR 6,423,111.21
Total securities with voting rights: 37,389,015 (all ordinary shares)
Total voting rights (denominator): 37,389,015
Unissued securities with voting rights: 2,039,481 granted subscription rights (excluding 643,394 issued but not granted)
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) received a transparency notification from BlackRock, Inc. on October 7, 2024, following changes in BlackRock's group structure. The notification, dated October 3, 2024, indicates that BlackRock, Inc. and its controlled undertakings now hold 1,116,421 voting rights, representing 3.25% of the total voting rights (34,389,015) as of October 1, 2024.
The holdings consist of 1,032,521 shares and 83,900 equivalent financial instruments. This change resulted from the acquisition of Global Infrastructure Partners, which led to a restructuring of BlackRock's group. The notification details the full chain of controlled undertakings and provides a breakdown of voting rights held by various BlackRock entities.
FAQ
What is the current stock price of Nyxoah SA Ordinary Shares (NYXH)?
What is the market cap of Nyxoah SA Ordinary Shares (NYXH)?
What is Nyxoah SA's core business?
What is the Genio system?
What conditions does Nyxoah's Genio system address?
How does Nyxoah update its stakeholders?
Where is Nyxoah SA headquartered?
What makes the Genio system unique?
What recent achievements has Nyxoah accomplished?
What is OSA?
Why invest in Nyxoah SA?